Posted on Mon, 10 Oct 2016 10:42:00 GMT By BIVDA
10th October 2016
Abingdon Health announce the CE marking of Seralite®-FLC ELISA, the latest addition to the Seralite® range. The introduction of an ELISA assay to measure serum free kappa and free lambda light chains means Abingdon Health now has the opportunity to offer its customers a simple, high throughput method for detecting and measuring serum FLC levels.
Posted on Thu, 07 Jul 2016 12:58:00 GMT By BIVDA
Organisation recommends simple blood test for diagnosing liver fibrosis in people with Non Alcoholic Fatty Liver Disease (NAFLD)
- An estimated 14 to 27 percent of the general population in the industrialised world has NAFLD1, which is often caused by obesity
- The ADVIA Centaur ELF Test is an easy, standardised, accurate, minimally-invasive blood test that measures liver damage, also known as fibrosis
- The ELF test is convenient to request compared to biopsy and/or scan, since it requires only a routine blood sample with test results available within an hour
Posted on Tue, 28 Jun 2016 13:00:00 GMT By BIVDA
Paris, France, and York, UK, June 27, 2016 – Sebia, the world leader in medical diagnostics by electrophoresis, and Abingdon Health, an in-vitro diagnostic group, today announce that they have entered into a multi-year, exclusive, global distribution agreement. The deal allows Sebia to add Abingdon Health’s Seralite®– FLC Dual Kappa and Lambda serum lateral flow immunoassay to its worldwide offering. The financial terms of the agreement have not been disclosed.
Posted on Fri, 27 May 2016 14:15:00 GMT By BIVDA
Belgium, May 2016 - Multiplicom, leader in diagnostics for personalized medicine, has received a Flanders Innovation & Entrepreneurship R&D grant of €1.9 million ($2.1 million) to support the development of advanced technologies and targeted NGS-based tests to enable early diagnosis, treatment and monitoring of cancers. With this grant, Multiplicom will accelerate its development of liquid biopsy based NGS cancer tests that will improve the quality of life of cancer patients.
Posted on Fri, 29 Apr 2016 14:32:00 GMT By BIVDA
Abingdon Health Ltd (“Abingdon Health”) today announces the signing of a collaboration agreement with Sumitomo Chemical Co., Ltd (“Sumitomo Chemical”) to develop a next generation multiplexed point of care biosensor device.
Posted on Thu, 28 Apr 2016 14:36:00 GMT By BIVDA
As the prevalence of cardiovascular disease (CVD) continues to grow, Rhys Tassell, Point of Care Testing Team Lead at Cambridge University Hospitals NHS Foundation Trust explains how Addenbrooke’s Hospital’s Emergency Department is ensuring a swift diagnosis at the point-of-care.
Posted on Mon, 22 Feb 2016 07:17:00 GMT By BIVDA
- A range of new assays has been released by Siemens for use on ADVIA Centaur and IMMULITE XPi 2000 systems
- Launch includes the first automated quantitative thyroid stimulating immunoglobulin (TSI) assay used in the diagnosis of Graves’ disease
Posted on Fri, 06 Nov 2015 15:51:00 GMT By BIVDA
As part of an exclusive distribution deal with Advance Diagnostic Products, Cambridge Life Sciences, is proud to offer Serum Indices Quality Controls which can routinely check the indices scanning performance of automated analysers.
Posted on Thu, 05 Nov 2015 15:54:00 GMT By BIVDA
5th November 2015 – Cobham, UK. From the 8th Clinical Trials on Alzheimer’s Disease (CTAD) in Barcelona, Proteome Sciences is pleased to announce that a recently completed study testing its proprietary inhibitors of casein kinase 1 delta (CK1d) reduced the level of tau phosphorylation in a second in vivo model of Alzheimer’s disease (AD) tauopathy.
Posted on Fri, 23 Oct 2015 15:58:00 GMT By BIVDA
Advanced smartphone-enabled medical device technology being developed in the UK is exactly the sort of rapid diagnostic test technology highlighted in a new Government report as being vital in stopping the unnecessary use of antibiotic